Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysisWorld J Urol 2022 May 21;[EPub Ahead of Print], T Yanagisawa, T Kimura, K Hata, S Narita, S Hatakeyama, K Mori, T Sano, T Otsuka, Y Iwamoto, Y Enei, M Nakazono, K Sakanaka, K Iwatani, A Matsukawa, M Atsuta, H Nishikawa, S Tsuzuki, J Miki, T Habuchi, C Ohyama, SF Shariat, S Egawa
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.